IL2 and melanoma: Until a decade ago the treatment options for melanoma patients were very limited and consisted mainly of highly toxic and poorly effective regimens based on chemotherapy [45–47] alone or in combination with immunotherapy with high doses of interleukin-2 (IL-2) [48,49] or interferon alpha (IFNa) [50].